India, Jan. 26 -- Eisai Co., Ltd. (ESALF.PK) and Biogen Inc. (BIIB) announced Sunday that the U.S. Food and Drug Administration has approved the Supplemental Biologics License Application (sBLA) for lecanemab-irmb, marketed as LEQEMBI in the U.S., to be administered once every four weeks.
LEQEMBI is prescribed for Alzheimer's disease (AD) in patients with mild cognitive impairment (MCI) or in the early dementia stage of the disease, collectively known as early AD, in the U.S. After an initial treatment phase lasting 18 months, during which the drug is administered once every two weeks, patients may transition to a maintenance dosing regimen of 10 mg/kg every four weeks, or they may continue with the biweekly dosing regimen.
LEQEMBI is app...